Your session is about to expire
← Back to Search
CoPILOT Training for Cognitive Impairment (CoPILOT Trial)
CoPILOT Trial Summary
This trial will test whether a new method of training people with cognitive impairments to use powered wheelchairs is more effective than the standard method. The new method, called CoPILOT, involves using a shared control wheelchair.
CoPILOT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCoPILOT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CoPILOT Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can use a powered wheelchair joystick.I have a visual or hearing impairment that could affect my safety during training.I have had a spinal cord injury.You have mild to moderate problems with thinking and memory.I am new to using powered wheelchairs or was previously denied one due to learning difficulties.
- Group 1: Standard of Care
- Group 2: CoPILOT
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are participants presently being enrolled for this experiment?
"This clinical trial is no longer open for recruitment, with the original posting and last update occuring on October 1st 2016 and May 25th 2018 respectively. However, there are an abundance of other trials that prospective participants may consider; in this moment 918 different studies have active enrolment processes."
Are there any potential dangers associated with the CoPILOT treatment?
"Limited data exists to attest to CoPILOT's safety and efficacy, so it was rated a 1 on our assessment scale."
Share this study with friends
Copy Link
Messenger